目的基于生物信息学分析平台探讨龟芍平颤方抗帕金森病的分子机制。方法从1994年4月~2019年12月的中英文数据库(中国期刊全文数据库、维普期刊全文数据库、中国生物医学文献数据库、中华本草、PubMed、Web of Science、SciFinder Schol...目的基于生物信息学分析平台探讨龟芍平颤方抗帕金森病的分子机制。方法从1994年4月~2019年12月的中英文数据库(中国期刊全文数据库、维普期刊全文数据库、中国生物医学文献数据库、中华本草、PubMed、Web of Science、SciFinder Scholar)中获得龟芍平颤方(龟甲、白芍、川芎、天麻)的化学成分,并于PubChem数据库中查找该方每种有效成分的人源活性靶蛋白。检索Gene数据库,查找帕金森病相关人源基因。将上述靶蛋白与基因上传至生物信息学分析平台,分析两者共同涉及的分子网络与生物学通路。结果获得龟芍平颤方人源活性靶蛋白323个(龟甲58个、白芍119个、川芎72个、天麻74个);获取帕金森病相关人源基因392个。建立上述靶蛋白及基因共同作用的主要分子网络,并甄选出G-蛋白偶联受体信号传导通路等10条主要的生物学通路。结论龟芍平颤方可能通过调控G-蛋白偶联受体信号传导通路等发挥抗帕金森病作用。展开更多
Big Data applications in the health service field have gradually been paid more close attention. Based on big data technology, more and more health information platforms are beginning to take effects, such as disease ...Big Data applications in the health service field have gradually been paid more close attention. Based on big data technology, more and more health information platforms are beginning to take effects, such as disease prevention, precision medicine, reducing expenditures for medical care and public health, improving medicine research and development. Meanwhile, the platforms have to face a lot of risks, such as health data disclosure, dispute of health data ownership, implicit contradiction explicit, unsustainable platform operation and so on. With the solutions of these risks, the construction of the public platform can provide better service for the citizens, hospital, pharmaceutical company, R&D institutions or and other parties.展开更多
文摘目的基于生物信息学分析平台探讨龟芍平颤方抗帕金森病的分子机制。方法从1994年4月~2019年12月的中英文数据库(中国期刊全文数据库、维普期刊全文数据库、中国生物医学文献数据库、中华本草、PubMed、Web of Science、SciFinder Scholar)中获得龟芍平颤方(龟甲、白芍、川芎、天麻)的化学成分,并于PubChem数据库中查找该方每种有效成分的人源活性靶蛋白。检索Gene数据库,查找帕金森病相关人源基因。将上述靶蛋白与基因上传至生物信息学分析平台,分析两者共同涉及的分子网络与生物学通路。结果获得龟芍平颤方人源活性靶蛋白323个(龟甲58个、白芍119个、川芎72个、天麻74个);获取帕金森病相关人源基因392个。建立上述靶蛋白及基因共同作用的主要分子网络,并甄选出G-蛋白偶联受体信号传导通路等10条主要的生物学通路。结论龟芍平颤方可能通过调控G-蛋白偶联受体信号传导通路等发挥抗帕金森病作用。
文摘Big Data applications in the health service field have gradually been paid more close attention. Based on big data technology, more and more health information platforms are beginning to take effects, such as disease prevention, precision medicine, reducing expenditures for medical care and public health, improving medicine research and development. Meanwhile, the platforms have to face a lot of risks, such as health data disclosure, dispute of health data ownership, implicit contradiction explicit, unsustainable platform operation and so on. With the solutions of these risks, the construction of the public platform can provide better service for the citizens, hospital, pharmaceutical company, R&D institutions or and other parties.